Customer Publication

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis

Authors: Kadefors, Måns et al.

Journal: Frontiers in Pharmacology (2022)

Institution: Department of Experimental Medical Science, Sweden

Research Areas: Pharmacology

Cell Lines: Primary human lung fibroblasts

Summary: Dipeptidyl peptidase 4 (DPP4) has been proposed as a marker for activated fibroblasts in fibrotic disease. The study aimed to investigate whether a profibrotic DPP4 phenotype is present in lung tissue from patients with idiopathic pulmonary fibrosis (IPF). The authors observed a reduced frequency of primary DPP4+ fibroblasts in IPF tissue using flow cytometry and an absence of DPP4+ fibroblasts in pathohistological features of IPF. This study provided evidence that DPP4-expressing fibroblasts are not involved in IPF. As such, DPP4 targeted therapy in IPF is unlikely to have a direct effect on fibroblasts HoloMonitor M4 was used for cell morphology, cell proliferation and cell motility.

Keywords: HoloMonitor M4, cell morphology, cell proliferation, cell motility, fibroblast, lung, fibrosis, idiopathic pulmonary fibrosis, dipeptidyl peptidase 4

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2